NEW
YORK — Biogen Idec, the maker of the multiple sclerosis pill Tecfidera,
expanded its partnership with Isis Pharmaceuticals in a deal worth at
least $100 million to develop drugs for neurological disorders. Biogen
will pay Carlsbad, Calif.-based Isis $100 million upfront and as much as
$220 million per compound in potential milestone payments, the
companies said Monday in a statement. The six-year deal gives Weston,
Mass.-based Biogen exclusive access to Isis’ antisense technology
platform to identify targets and develop drugs for neurological
diseases.Assessing risks of multiple sclerosis therapies.
Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne,
Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Ferkauf Graduate School of Psychology, Yeshiva University, United States; Multiple Sclerosis Center of Holy Name Medical Center, United States
Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis.
New Zealand Brain Research Institute, , Christchurch, New Zealand.: Debernard L, Melzer TR, Van Stockum S, Graham C, Wheeler-Kingshott CA, Dalrymple-Alford JC, Miller DH, Mason DF. J Neurol Neurosurg Psychiatry. 2013 Sep 13.
Grey matter (GM) pathology in multiple sclerosis (MS) is associated with progressive long-term disability. Detection of GM abnormalities in early MS may therefore be valuable in understanding and predicting the long-term course. However, structural MRI measures such as volume loss have shown only modest abnormalities in early relapsing-remitting MS (RRMS). We therefore investigated for evidence of abnormality in GM perfusion, consistent with metabolic dysfunction, in early RRMS.
The decrease in GM perfusion in the absence of volume loss is consistent with neuronal metabolic dysfunction in early RRMS. Future studies in larger cohorts and longitudinal follow-up are needed to investigate the functional and prognostic significance of the early GM perfusion deficits observed.
Bipolar disorder and multiple sclerosis: A case series.
Department of Neurology, Razi Hospital, Mannouba, Tunis, Tunisia.: Sidhom Y, Djebara MB, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, Gouider R.
Behav Neurol. 2013 Sep 12. [Epub ahead of print]
Delayed Recovery of Leg Fatigue Symptoms Following a Maximal Exercise Session in People With Multiple Sclerosis.
1Oxford Brookes University, Oxford, UK.: Dawes H, Collett J, Meaney A, Duda J, Sackley C, Wade D, Barker K, Izadi H.
Neurorehabil Neural Repair. 2013 Sep 11.
Symptoms of fatigue were investigated during and following a single exercise session.
Monitoring leg fatigue symptoms during and through recovery from physical activities may help guide participation in physical activities for PwMS, particularly in people managing high levels of fatigue.
Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption.
J Neuroimmunol. 2013 Sep 15;262(1-2):19-26.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Cladribine causes sustained reduction in peripheral T and B cell populations while sparing other immune cells. We determined two populations of dendritic cells (DCs): namely CD1c(+)/CD19(-) (myeloid DCs) and CD303(+)/CD123(+) (plasmacytoid DCs), CD19(+) B lymphocytes, CD3(+) T lymphocytes and CD4(+) or CD8(+) subpopulations in patients with multiple sclerosis after cladribine therapy. We noticed significant trend to increase the CD303(+) circulating the dendritic cells. This population produces large amounts of IFN-alfa. We found significant and rapid decrease in B cells and CD4(+) Th cells. Our results suggest two possible ways of beneficial cladribine influence on immune system in MS. Induction of IFN-alfa producing cells and their predominance over BDCA-1(+) DCs, which are associated with cytotoxic response. Additionally, cladribine could influence two populations of lymphocytes: B cells and Th lymphocytes responsible for induction of immune response against myelin antigens.
Intrathecal oligoclonal IgG synthesis in multiple sclerosis.
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology, Neuroimmunology & CSF Laboratory, Queen Square, London, United Kingdom. Electronic address: a.petzold@vumc.nl.: J Neuroimmunol. 2013 Sep 15;262(1-2):1-10
Inez Wens, Ulrik Dalgas, Egon Stenager, and Bert O. Eijnde
Multiple Sclerosis Journal. published 18 September 2013
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Ralph HB Benedict, Hanneke E Hulst, Niels Bergsland, Menno M
Schoonheim, Michael G Dwyer, Bianca Weinstock-Guttman, Jeroen JG
Geurts, and Robert Zivadinov
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
Ralph HB Benedict, Hanneke E Hulst, Niels Bergsland, Menno M
Schoonheim, Michael G Dwyer, Bianca Weinstock-Guttman, Jeroen JG
Geurts, and Robert Zivadinov
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
Su-Hyun Kim, So-Young Huh, Woojun Kim, Min Su Park, Suk-Won Ahn,
Joong-Yang Cho, Byung Jo Kim, and Ho Jin Kim
Multiple Sclerosis Journal. 2013; 19(11): p. 1493-1498
Joong-Yang Cho, Byung Jo Kim, and Ho Jin Kim
Multiple Sclerosis Journal. 2013; 19(11): p. 1493-1498
Joseph R Berger, Jennifer Pocoski, Ronald Preblick, and Susan Boklage
Multiple Sclerosis Journal. 2013; 19(11): p. 1526-1532
Multiple Sclerosis Journal. 2013; 19(11): p. 1526-1532
J Frau, D Cossu, G Coghe, L Lorefice, G Fenu, M Melis, D Paccagnini, C
Sardu, MR Murru, S Tranquilli, MG Marrosu, LA Sechi, and E Cocco
Multiple Sclerosis Journal. 2013; 19(11): p. 1437-1442
Sardu, MR Murru, S Tranquilli, MG Marrosu, LA Sechi, and E Cocco
Multiple Sclerosis Journal. 2013; 19(11): p. 1437-1442
Multiple Sclerosis Journal. 2013; 19(11): p. 1473-1477
Multiple Sclerosis Journal. 2013; 19(11): p. 1462-1472
